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Abstract:  Specific  treatment  is  not  available  for  human  botulism.  Current  remedial 
mainstay  is  the  passive  administration  of  polyclonal  antibody  to  botulinum  neurotoxin 
(BoNT)  derived  from  heterologous  species  (immunized  animal  or  mouse  hybridoma) 
together  with  supportive  and  symptomatic  management.  The  antibody  works 
extracellularly, probably by blocking the binding of receptor binding (R) domain to the 
neuronal receptors; thus inhibiting cellular entry of the holo-BoNT. The antibody cannot 
neutralize the intracellular toxin. Moreover, a conventional antibody with relatively large 
molecular  size  (150  kDa)  is  not  accessible  to  the  enzymatic  groove  and,  thus,  cannot 
directly  inhibit  the  BoNT  zinc  metalloprotease  activity.  Recently,  a  15–20  kDa  single 
domain antibody (VHH) that binds specifically to light chain of BoNT serotype A was 
produced  from  a  humanized-camel  VH/VHH  phage  display  library.  The  VHH  has  high 
sequence homology (>80%) to the human VH and could block the enzymatic activity of 
the BoNT. Molecular docking revealed not only the interface binding between the VHH 
and the toxin but also an insertion of the VHH CDR3 into the toxin enzymatic pocket. It is 
envisaged  that,  by  molecular  linking  the  VHH  to  a  cell  penetrating  peptide  (CPP),  the  
CPP-VHH fusion protein would be able to traverse the hydrophobic cell membrane into the 
cytoplasm  and  inhibit  the  intracellular  BoNT.  This  presents  a  novel  and  safe 
immunotherapeutic  strategy  for  botulism  by  using  a  cell  penetrating,  humanized-single 
domain antibody that inhibits the BoNT by means of a direct blockade of the groove of the 
menace enzyme. 
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1. Introduction  
Botulism is a severe paralytic illness caused by intoxication with botulinum neurotoxins (BoNT) 
produced by anaerobic bacteria of the genus Clostridium, Clostridium botulinum [1–3]. BoNT is one 
of the most toxic substances for humans [4]. From primate experiments, the toxin has an extremely 
low median lethal  dose (LD50), i.e.,  1 ng per kg  body weight  [5]. BoNT  is  transmitted easily by  
aerosol [5]. Accordingly, the toxin has been attempted by terrorists to use as a biological weapon. 
BoNT  has  been designated by the  Centers for  Disease Control  and Prevention (CDC), USA  as  a 
category A biological weapon, which is a similar to anthrax in its threat to humans [4,5]. 
1.1. Botulinum Neurotoxins (BoNTs) 
There are seven BoNT serotypes designated A–G serotypes (BoNT/A-BoNT/G). C. botulinum, a 
spore forming, rod shape anaerobic bacterium produces mainly BoNT/A, BoNT/B, BoNT/C, BoNT/D, 
BoNT/E, and BoNT/F. BoNT/G is solely produced by C. argentinense; C. butyrium produces BoNT/E, 
and C. baratii produces BoNT/F [1,3]. Among the seven serotypes, BoNT/A is the most potent for 
humans [2]. Naturally, BoNT is associated to other bacterial proteins, i.e., hemagglutinin (HA) and 
non-toxic, non-hemagglutinin (NTNH) protein in a form of BoNT-HA-NTNH complex [3]. Although 
functions of the clostridial HA and the NTNH proteins are still unknown, it is believed that forming a 
complex with these proteins not only renders the BoNT more resistant to the host gastric acidity, but 
also facilitates the toxin entry into the blood circulation by undefined mechanism [6,7]. 
1.2. Synthesis and Molecular Structure of BoNTs 
BoNT  are  encoded  by  bont  genes  (~3880  bp)  which  are  present  on  various  genetic  elements, 
depending on the species and strains of BoNT-producing clostridia [7]. The bont genes that code for 
BoNT/A, BoNT/B, BoNT/E and BoNT/F (bont/A, some bont/B, bont/E and bont/F) are located on the 
bacterial chromosome [7–9];  bont/C  and  bont/D  are derived from bacteriophages  [10,11];  and the 
bont/G and some bont/B genes are present on plasmids [12,13]. Sequence similarity of the bont genes 
coding for the seven BoNT serotypes ranged from 34% to 97% [7]. 
The molecular structure of BoNTs has been revealed by crystallography as an A-B toxin [14,15]. It 
is  believed  that  the  two  polypeptides  are  synthesized  as  a  single  polypeptide  which  is  modified  
post-translationally  by  bacterial  or  host  proteases  to  a  150  kDa,  active  di-chain  holotoxin.  Each 
molecule of the toxin is composed of an A subunit or light chain (LC, size ~50 kDa) which is linked to 
a B subunit or heavy chain (HC, size ~100 kDa) by a single disulfide bond. HC composed of two 
polypeptide sub-domains, i.e., receptor binding (R) and translocation (T). LC of the BoNT is endowed Toxins 2011, 3                         
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with  zinc-dependent  metalloprotease  activity  [16].  Schematic  diagram  of  BoNT/A  synthesis  is 
illustrated  in  Figure  1.  The  sequence  variations  of  BoNT  are  in  the  R  domain  and  the  substrate 
interaction sites of LC domain [14,17].  
Figure 1. Schematic diagram of BoNT/A synthesis. Gene coding for BoNT/A (bont/A) 
synthesized a single polypeptide which is then nicked to form a di-chain active BoNT/A. 
LC, BoNT/A light chain (residues 1–437); HC, BoNT/A heavy chain (residues 448–1295); 
T, translcation sub-domain (residues 448–872); R, receptor binding sub-domain (residues 
873–1295). A di-sulfide bond is formed by cysteine residues 430 and 454 [18].  
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1.3. Mechanism of Action of BoNTs 
Ingested BoNT absorbed from the intestine, enters lymphatics which are later carried by blood 
circulation  and  distributed  throughout  the  host  tissues  [19].  At  a  peripheral  nerve  ending,  the  R  
sub-domain  binds  to  two  receptors  of  the  neuron,  i.e.,  low-affinity  gangliosides  and  high-affinity 
synaptic vesicular proteins [20,21]. The synaptic vesicular proteins that serve as the BoNT receptors 
are normally located within the lumen of acetylcholine-containing vesicles but become exposed after 
the neurotransmitter release. Synaptic vesicular proteins that have been identified as  BoNT/A and 
BoNT/B  receptors  are  synaptic  vesicular  protein-2  (SV2)  [22]  and  synaptotagmin-II  (SytII), 
respectively  [20,21].  The  BoNT  that  has  bound  to  the  neuronal  surface  receptors  then  enters  the  
cell via the receptor-mediated endocytosis (RME). Acidic pH of the endosome facilitates structural 
change  of  the  T  sub-domain,  which  forms  a  putative  pore-like  structure  [23,24].  The  partially  or 
completely unfolded LC translocates across the endosomal membrane via the T-forming pore into the 
cytoplasm [24,25]. The free LC then refolds and specifically cleaves one of soluble N-ethylmaleimide-
sensitive  factor-attachment  protein  receptor  (SNARE)  proteins  including  synaptobrevin  (or  vesicle 
associated  membrane  protein;  VAMP)  which  anchors  on  outer  shell  of  synapticular  vesicle,  
synaptosomal-associated protein of 25 kDa (SNAP25), and syntaxin. The latter two are associated with 
the  inner  leaflet  of  the  neuronal  plasma  membrane  [26].  BoNT/A,  BoNT/C  and  BoNT/E  cleave 
SNAP25  at  different  peptidase  sites  [27–29].  BoNT/C  also  digests  syntaxin  [25,30,31].  BoNT/B, Toxins 2011, 3                         
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BoNT/D, BoNT/F, and BoNT/G cleave synaptobrevin [7]. Table 1 gives details on the target SNARE 
proteins  of  the  BoNTs  and  their  specific  endopeptidase  cleavage  sites.  The  cleavage  of  SNARE 
proteins, which are neurotransmitter exocytosis machinery, leads to abolition of the membrane fusion 
between  neurotransmitter-containing  vesicles  and  the  neuronal  plasma  membrane,  and  eventually 
blocks acetylcholine release to neuromuscular junction, resulting in weakness of muscles or flaccid 
paralysis; the disease which is called botulism [5,26]. 
Table 1. Cleavage sites of different BoNTs on the human SNARE proteins [18]. 
BoNT Serotype  SNARE Substrate(s)  Susceptible Scissile Bond  Reference(s) 
A  SNAP25  Gln197-Arg198  [27–29] 
C  SNAP25  
Syntaxin 
Arg198-Ala199 
Lys253-Ala254 and 
Lys260-Ala261 
[30,31] 
[25,30,31] 
E  SNAP25  Arg180-Ile181  [28,29] 
B  VAMP  Gln76-Phe77  [32] 
D  VAMP  Lys59-Leu60  [28,34] 
F  VAMP  Gln58-Lys59  [33,34] 
G  VAMP  Ala81-Ala82  [35] 
1.4. Botulism  
Botulism  is  the  weakness  of  the  affected  striated  muscles  (flaccid  paralysis)  due  to  the  BoNT 
mediated blockade of the release of acetylcholine neurotransmitter from pre-synaptic neuron into the 
neuromuscular  junction  [26].  Human  botulism  is  caused  by  BoNT/A,  BoNT/B,  BoNT/E,  and 
occasionally BoNT/F. Domesticated animals including dogs, cattle, birds, and chickens are affected by 
BoNT/C. BoNT/D can cause the disease in cattle. There has been no reported case of human or animal 
botulism associated with BoNT/G [3,5,36]. 
Four  clinical  types  of  human  botulism  have  been  identified.  They  are:  food-borne-,  infant-,  
wound- and inhalational botulism [5]. Food-borne botulism is manifested after ingesting improperly 
cooked,  preserved  or  stored  foods,  especially  canned  food  containing  preformed  BoNT.  Under 
anaerobic conditions, bacterial spores that have contaminated the food germinate and release the BoNT 
by a cell-wall exfoliation mechanism. Unlike food-borne botulism, infant botulism is caused by BoNT 
released from growing clostridia that colonize in infant’s intestine [1,5]. In wound botulism, clostridia 
colonizes an infected injured tissue, produce toxins which later absorbed into the bloodstream of the 
host, and subsequently reach the neuromuscular junctions [1,5]. The inhalational form of botulism is 
man-made and caused by inhalation of the BoNT powder, which is aerosolized and transmitted to 
victims for the purpose of bioterrorism [5]. Among the four types, food-borne botulism is the most 
common type [1,5]. Clinical manifestations of the food-borne botulism usually begin 12 to 48 h after 
ingesting the food contaminated with the preformed BoNT [5,7].  
1.5. Clinical Manifestations of Human Botulism [5,36] 
All forms of human botulism present mostly identical neurological signs because all BoNT mediate 
similar physiological abnormalities in the peripheral nervous system. However, the neurological signs Toxins 2011, 3                         
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in food-borne botulism may include abdominal cramps, nausea, and vomiting. The neurological form 
is  characterized by symmetrical,  descending, and flaccid  paralysis of parasympathetic nerves.  The 
symptoms usually begin with cranial nerve (face) palsies, including drooping of the upper eyelids 
(ptosis), double vision (diplopia), blurred vision, difficulty in articulating words (dysarthria), difficulty 
in speaking (dysphonia), and difficulty in swallowing (dysphagia). The paralysis then develops to 
general weakness of several muscles such as arms, legs, and diaphragm which may lead to fatality if 
not treated properly and promptly. The severity of the disease varies from individual to individual and 
depending upon the amount of toxins consumed and absorbed [5]. 
2. Treatment of Botulism 
Presently,  there  is  no  licensed  BoNT  antagonist,  although  several  attempts  have  been  made  to 
invent  the  toxin  inhibitors.  Mouse  monoclonal  antibodies  to  BoNT  light  chain  were  unable  to 
neutralize the BoNT mediated lethality in mice, although the antibodies injected intracellularly into 
nerve ganglion prior to the BoNT administration were found to prevent the BoNT mediated inhibition 
of neurotransmitter exocytosis  in  Aplysia [37]. Small  molecular  inhibitors of  S1 subsite of type  B 
BoNT metalloprotease were shown to inhibit the BoNT activity in vitro [38,39]. However, due to their 
inability  to  cross  plasma  membrane,  none  of  them  have  reached  the  clinical  trial  for  the  human 
therapeutic value.  
The  treatment  of  botulism  is  based  on  supportive  measures  including  artificial  respiration  and 
passive  administration  of  human  and  animal  (mainly  horse)  derived  anti-BoNT  immune  globulin 
(polyclonal antibodies; PAb) to the afflicted individual [5]. Immune sera and antibody preparations 
that have been used for treatment of human botulism are listed in Table 2.  
Table 2. Various anti-BoNT preparations for current therapeutic use. 
Preparation  Target BoNT 
Serotype  
Enterpreneur  Status  Reference(s) 
1.  Trivalent equine 
antitoxin  
A, B, and E  CDC/USA  FDA approved  [36,40] 
2.  Bivalent equine 
antitoxin (BAT-AB)  
A and B  Sanofi Pasteur Limited  FDA approved  [41,42] 
3.  Human botulism 
immune globulin 
(BabyBIG or BIG-IV) 
A,B,C,D, and E  California Department 
of Public Health 
FDA approved  [41–44] 
4.  Monovalent equine 
antitoxin (BAT-E)  
E  Sanofi Pasteur Limited  Investigational  [41] 
 
5.  Heptavalent equine 
antitoxin (HBAT) 
A to G  Cangene Corporation  Investigational  [41] 
6.  Recombinant antitoxin  A  University of California, 
San Francisco 
Investigational  [36,45–47] 
There are some limitations in using the immunized human/animal derived antitoxin. It is believed 
that the PAb derived from the immune serum can only block the circulating BoNT from cellular entry 
by inhibiting the binding of the toxin to the neuronal cell surface receptors  [48,49].  They cannot Toxins 2011, 3                         
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traverse  the  plasma  membrane.  The  preparation  usually  contains  a  relatively  small  proportion  of 
specific immunoglobulins. Moreover, the animal-derived anti-BoNT is foreign to the human immune 
system. Therefore, not only are the antibodies speedily eliminated from the recipient’s body (hence 
large amount of the therapeutic antibodies are required to resuscitate the patient), but also the animal 
proteins elicit anti-animal isotypic response leading to adverse reactions which may be as serious as 
acute anaphylaxis and/or serum sickness [5]. The latter is mediated by immune complexes formed in 
the  condition  of  the  antigen  (animal  protein)  excess.  Besides,  the  supply  and  availability  of  the 
antitoxin  are  relatively  limited  because  a  prolonged  immunization  process  is  required  before  a 
satisfactory  level  of  the  antitoxin  is  reached  in  the  sera.  The  quality  of  the  BoNT  neutralizing 
antibodies obtained in this way is subjected to batch-to-batch variation. The human recipient is also at 
a  risk  of  anthroponosis/zoonosis.  Therefore,  alternative  approaches  for  producing  the  botulism 
therapeutic antibody should be sought. 
3. Therapeutic Antibody 
3.1. Serum Therapy 
Antibody has been used since the early nineteenth century in passive immunization for disease 
prevention and intervention as well as for therapeutic purposes [50]. The medical practice was then 
called ―Serum therapy‖. The therapeutic preparations were either immune serum or immunoglobulins 
derived  from  plasma  or  serum  of  healthy,  vaccinated  and/or  disease  convalescent  humans.  For 
example, the serum of a human immunized with tetanus toxoid was used for treatment of tetanus [51]; 
and  the  serum  of  a  convalescing  measles  patient  was  used  in  the  intervention  of  measles  
morbidity in an immunocompromised child who had been exposed to the measles virus [52]. The 
immunoglobulin/antibody therapeutic role include restoration of the immunoglobulin functions in the 
immunodeficient  subjects,  toxin/enzyme  neutralization,  prevention  of  pathogen  attachment  to  host 
cell/tissue  and  colonization,  prevention  of  cellular  entry,  inhibition  of  motility,  promotion  of 
phagocytosis by means of opsonization followed by killing, immune exclusion, antibody dependent 
cell mediated cytotoxicity (ADCC) by natural killer (NK) cells and antibody-complement mediated 
lysis of pathogens or infected host cells [53–58]. Limitations in using human derived antibody include 
the  scarcity  of  donors,  variation  in  antibody  quality,  and  recipient  risk  to  some  blood-borne 
anthroponosis.  The  practice  is  also  unethical.  Thus,  therapeutic  antibodies  were  from  immunized 
animals such as horse or sheep. Nevertheless, there are still problems in production and use of the 
animal-derived antibody. Repetitive immunizing doses and a prolonged immunization process (more 
than 6 months or a year) are required before a satisfactory level of antibody is obtained from the 
plasma/serum of the immunized animal. There is a batch-to-batch variation in the antibody quality. 
Using in vivo immunization, it is difficult to produce immune serum for low immunogenic and/or 
highly toxic molecules (such as snake neurotoxin), for which the immunogenic dose is much higher 
than the toxic/lethal dose, similarly for small molecular hapten that contain only B cell epitope, such as 
puffer fish tetrodotoxin (~320 Da). Besides, large animals require a large amount of space and care. 
Animal immune serum contains a large proportion of non-specific serum proteins/immunoglobulins. 
Most of all, animal proteins are foreign and highly immunogenic to the human immune system, often Toxins 2011, 3                         
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leading to allergic reactions such as anaphylaxis and serum sickness—the latter is caused by human 
anti-animal  isotypic  antibodies  which  form  an  immune  complex  with  the  animal  proteins.  The 
recipient is also at risk of zoonosis.  
3.2. Mouse Monoclonal Antibody 
The invention of hybridoma technology by Kö hler and Milstein (subsequent recipients of Nobel 
Laureates) in 1975 [59] has abrogated many limitations in preparing and using the animal immune 
serum. The mouse monoclonal antibody (MAb) with high purity, defined specificity, and reproducible 
affinity [60] can be obtained easily, rapidly, and adequately without frequent/repeated and prolonged 
immunization process but merely by growing an established hybridoma clone in a culture medium. 
The recipients of the MAb are relatively safe from zoonosis as the MAb can be obtained from the 
spent culture medium of a hybridoma grown in a serum free medium. Nowadays, murine MAb have 
been  used  as  therapeutic  agents  against  cancers,  autoimmune,  inflammatory  conditions,  infectious 
diseases, and intoxications [53,61]. Currently, about 30 therapeutic antibodies have been approved by 
FDA for marketing in the United States and over 200 MAb candidates are in the pipeline [62,63]. 
Recently, MAb specific to HC of BoNT subtype A1 were produced [64]. The MAb and its pegylated 
F(ab)’2 not only neutralized the BoNT activity but could rescue the intoxicated mice from the toxin 
mediated lethality [64]. Nevertheless, limitations in production of MAb include requirement of tissue 
culture facility. Often the culture is  contaminated and the hybrid  clone loses the immunoglobulin  
genes [65]. Biologically, the mouse MAb is foreign to the human immune system and the human 
antibody  to  mouse  antibody  (HAMA)  is  produced  inevitably  which  also  leads  to  adverse  
effects [66–68]. Ideally, an antibody with minimal- or, to the best, no immunogenicity to the human 
immune system is needed for human therapy.  
3.3. Chimeric-, Humanized- and Single Chain Antibodies 
The first  attempt to  reduce immunogenicity of  the  mouse MAb in  the human recipient  was  to 
produce a human-mouse chimeric antibody [69]. The Fc portion of the mouse antibody was replaced 
by the human counterpart in the chimeric molecule by genetic engineering. The Fc is required to retain 
effective  therapeutic  mechanisms  (Section  3.1)  and  longevity  as  well  as  for  clearing  the  immune 
complexes  by  means  of  Fc-dependent  phagocytosis.  The  chimeric  antibody  retains  the  original 
antigenic (epitopic) specificity of the mouse MAb but about 70% or more of the molecule is human 
protein [70]. F(ab)’2, Fab or single chain  antibody fragments  (ScFv; VH linked to  VL by a short 
polypeptide)  can  be  used  in  human  therapy  when  the  bio-function  of  the  Fc  in  mediating  the 
therapeutic  effect  is  not  needed.  Clearance  of  the  immune  complexes  formed  by  these  antibody 
fragments can be mediated by Fc-independent phagocytosis [71,72]. The immune aggregates and small 
molecules  (e.g.,  free  ScFv)  may  be  filtered  through  glomeruli  for  which  the  filtration  cut-off  is 
approximately  60  kDa  [73].  However,  HAMA  is  still  produced  against  the  mouse  antibody  
fragments  [66,67].  Further  reduction  of  the  immunogenicity  of  the  mouse  protein  in  the  human 
recipient  has  been done by replacing the mouse immunoglobulin  frameworks  (FRs) with  the best 
matched  human  counterparts.  This  can  be  done  by  the  molecular  grafting  of  all  of  the  mouse 
complementary determining region (CDR) coding sequences onto the DNA sequences of human FRs; Toxins 2011, 3                         
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the process is called ―Humanization‖ [74,75]. The humanized-mouse monoclonal antibody fragments 
such as ScFv retain the original epitopic specificity, but the mouse protein is contained only in the 
CDRs  and  is  unlikely  to  be  immunogenic  in  humans.  The  first  chimeric  (antithrombolism)  and 
humanized (immunosuppressant) antibodies for human use were approved by the FDA in 1994 and 
1997,  respectively  [76].  For  anti-BoNT,  several  chimeric,  humanized  and  ScFv  are  currently  in  
pre-clinical evaluation [45–47].  
3.4. Fully Human Monoclonal Antibody 
The production of fully human therapeutic monoclonal antibody is possible nowadays by using 
several approaches. Transgenic mice carrying human immunoglobulin genes can be immunized with 
an antigen. The animals produce human polyclonal antibodies which are the products of the human 
immunoglobulin transgenes [77]. However, the supply of the human polyclonal antibodies from the 
transgenic mice is limited and expensive and thus they are limited to research purposes. Spleen cells of 
the immunized transgenic mice can be fused with mouse myeloma cells, and hybridomas secreting 
human monoclonal antibodies can be produced by conventional hybridoma technology. However, the 
transgenic facility and the cost of transgenic mice are hardly affordable by most developing countries. 
The alternative production of a fully human monoclonal antibody is done by infecting human immune 
B lymphocytes from immunized/disease convalescing subjects with Epstein-Barr (EB) virus [78–80]. 
The virus transforms the B cells into immortalized cells which can be grown individually in tissue 
culture  for  human  monoclonal  antibody  production.  Nevertheless,  the  EB  transformed  B  cells 
frequently lose the ability to secrete the MAb [81].  
Theoretically, the human immune system can generate approximately 10
12 of antibody diversity 
from  a  rather  limited  immunoglobulin  gene  repertoire  by  means  of  several  notated  mechanisms 
including:  the  use  of  multiple  germ-line  gene  segments,  combinatorial  V-(D)-J  joining,  junctional 
flexibility of coding joints, P-region nucleotide addition, N-region nucleotide insertion for H chains, 
combinatorial association of L and H chains, and somatic hypermutation and affinity maturation in 
secondary lymphoid tissues [82,83].  
Contemporary  technology  in  molecular  biology  and  molecular  immunology  such  as  antibody 
engineering  also  allows  the  possibility  of  making  a  specific  human  antibody  with  relatively  high 
affinity to a target molecule  in vitro (without the in vivo immunization). For instance, the human 
immunoglobulin gene repertoire could be generated in vitro by cloning the antibody coding genes from 
B lymphocytes of naï ve or specifically immunized donors into a display system, such as cell [84–86], 
ribosome [87], and phage [88] to construct the so-called ―Human antibody display library‖ [89,90]. 
Among these display systems, phage is the most commonly used for constructing the antibody display 
library [89]. The antibody molecules; mostly in the fragment formats  (Fab, ScFv, single antibody 
domain)  [91],  are  displayed  on  the  surface  of  fd  or  M13  filamentous  bacteriophages  which  the 
phenotype of each displayed molecule is correlated to the genotype of the encoding DNA in the phage 
genome [92]. To construct such a recombinant antibody phage display library, a pool of differently 
rearranged  immunoglobulin  genes  is  amplified  and  cloned  into  a  phagemid  vector  (a  plasmid 
containing a phage origin of replication). The translation frame of the gene is positioned next to gIII or 
gVIII, which code for phage pIII minor coat protein and pVIII major coat protein respectively [93,94]. Toxins 2011, 3                         
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There is an amber stop codon (TAG) incorporated between the inserted antibody gene and  gIII or  
gVIII [93]. In the suppressor E. coli strain, the suppressor tRNA is produced, which allows reading 
through the amber codon so that the antibody is displayed on the phage surface by fusing with the pIII 
or pVIII protein [93]. In contrast, non-suppressor E. coli strain does not produce such a tRNA; thus the 
recombinant antibody is secreted alone without the pIII or pVIII phage partner [93]. The recombinant 
phagemid-carrying  antibody  gene  insert  will  replicate  in  the  suppressor  E.  coli.  Mature  phage 
(complete) phage particles are obtained after co-infecting the cultured phagemid transformed E. coli 
with  a  helper  phage  such  as  M13K07,  so  called  ―Phage  rescue‖  process.  The  newly  assembled 
recombinant phage particles display the antibody molecules on their surface as pIII- or pVIII-fusion 
protein. The co-infection of the recombinant phagemid transformed E. coli with the helper phage is 
indispensible because the phagemid genome only encodes the pIII or pVIII fusion proteins without 
other genes for all other essential structural phage proteins; thus the mature phage particles cannot be 
produced. The phage structural proteins must be provided by the helper phages. The helper phages also 
help in packaging the replicating recombinant phagemids into the capsid. After phage rescuing, some 
new helper phages could be obtained in the phage library [93]. Nevertheless, they are less competitive 
for assembling into complete particles than the recombinant phagemids because of their defect in the 
origin of replication [93]. 
A  phage  that  displays  an  antibody  to  a  particular  antigen  can  be  directly  isolated  from  the 
constructed antibody phage display library by means of ―Bio-panning‖. An antigen is immobilized on 
a  solid  phase,  such  as  cell  surface,  beads,  or  wells  of  ELISA  plate.  The  antigen  binds  with  the 
displayed-antibody molecule on the phage particle. The antigen-unbound phages are removed simply 
by  extensive  washing  with  a  buffer  such  as  phosphate  buffered  saline  (PBS)  containing  a  mild 
detergent, e.g., Tween-20 (PBST). The antigen-bound phages can be eluted, further amplified in the 
suppressor E. coli and rescued from the culture after adding the helper phage. They can be subjected to 
repeated  bio-panning  rounds  in  order  to  enrich  the  high  affinity  binders  [93].  Alternatively,  the 
antigen-bound phages from the single bio-panning round can be added directly with a non-suppressor 
strain of E. coli host cells to allow phage transfection into the bacteria. In our laboratory, this ―Single 
round bio-panning‖ has been used successfully for the selection of recombinant phage clones that 
display specific antibodies to a variety of target molecules [90,95–97]. In the E. coli transfection, each 
recombinant phage uses the unoccupied pIII molecule(s) to bind to the bacterial F pilus. The latter 
serves as a molecular tube through which the phagemid genome with the antibody gene insert enters 
the bacterial cytoplasm. The phage-transfected E. coli colonies grow on a selective agar plate and can 
be selected appropriately [90,95–97]. The selected transformed non-suppressor E. coli can be grown 
under an induction condition (usually by isopropyl β-D-1-thiogalactopyranoside; IPTG) to express the 
soluble  recombinant  antibody  molecules  with  fusion  tags  such  as  E-tag.  The  tagged  recombinant 
antibody can be detected and purified easily by using anti-tag monoclonal antibody as the capture 
reagent. The bacterial expression system allows a production of the fully human recombinant antibody 
at the desired quantity without the in vivo immunization [93,98]. In addition, the antibody coding gene 
can be subcloned from the phagemid into other appropriate vectors for antibody production by other 
cellular factories such as insect, yeast and mammalian. The antibody display technology allows also 
the production of antibodies to low immunogenic, non-immunogenic and/or toxic molecules which are 
highly difficult, if possible, by a conventional immunization method. The in vitro production is free Toxins 2011, 3                         
 
 
478 
from an in vivo immune regulation and feedback mechanism. The antibody recipient is safe from 
zoonosis. Moreover, the antibody production is free from the animal ethic and welfare concern.  
3.5. Single Domain Antibody (sdAb) 
Serum  of  some  camelids,  i.e.,  Camelus  dromedarius  (one  hump  Arabian  camel),  llama  (Lama 
glama and L. guanicoe) and alpaca (Vicugna pacos) contains both a conventional four-chain antibody 
and an atypical antibody, called ―Heavy-chain antibody (HCAb)‖ the molecule of which does not 
contain  a  light  chain.  Instead,  two  heavy  chain  molecules  tend  to  be  associated  by  non-covalent 
bonding [99]. HCAb has one antigen-binding site per molecule and this is contributed by the heavy 
chain  variable  domain  designated  ―VHH‖  instead  of  the  typical  VH  and  VL  of  the  conventional  
four-chain antibody. Because the HCAb lacks VL, the hydrophobic amino acids V42, G49, L50, and 
W52 of the conventional VH where the VL partner used to associate were replaced by hydrophilic 
counterparts, i.e., F/Y42, E49, R/C50, and G/L52 in the FR2 of the VHH in order to reduce molecular 
aggregation and increase serum solubility of the HCAb [100,101]. The amino acid tetrad is a hallmark 
that allows distinction to be made between the VHH of HCAb and the conventional VH.  
Diversity of the HCAb repertoire is generated from the germline immunoglobulin DNA by the same 
mechanisms  as  for  humans  and  mice,  except  that  the  combinatorial  H-L  chain  pairing  is  absent 
because  of  the  lack  of  the  L  chain  partners  [102,103].  The  HCAb  diversity  was  from:  multiple  
germ-line gene segments, combinatorial V-D-J joining, junctional flexibility, P-nucleotide addition and  
N-nucleotide insertion. Somatic hypermutation and affinity maturation also occur in the secondary 
lymphoid tissues [103]. The camelid immune system compensates for the absence of combinatorial  
H-L  chain  pairing  by  using  several  other  strategies  which  have  been  described  in  more  detail  
elsewhere  [103].  Briefly,  the  HCAb  VHH  segments  have  expanded  surface  for  antigen-contact 
especially in the CDR1 and CDR3 [102]. CDRs of the VHH are unusually longer than the CDRs of the 
conventional VH; for example, CDR1 and CDR3 of VH have 5 and 12 amino acids respectively, while 
VHH CDR1 and CDR3 have 8 and 16–18 amino acids respectively [103,104]. It is believed that the 
longer CDR3 of camel VHH is facilitated by an increased activity of the TdT enzyme (N-nucleotide 
insertion) during the V-D-J joining [105]. Besides, there are several hotspots for somatic mutations by 
the oligonucleotide insertions and deletions in VHH DNA which are frequently found at CDR1 and 
CDR2 [102,105]. Moreover, the camel VHH segments have structural hypervariability of the antigen 
binding  loops  created  by  non-canonical  extra-loop  disulfide  bonds  in  the  CDRs,  including  CDR3  
intra-loop disulfide bonds and the inter-loop disulfide bonds that link the CDR3 with CDR1 or CDR2 
and with FR2 [100,106]. 
4. Molecular Insertion of a Single Domain Antibody (sdAb) into the Enzymatic Groove Directly 
Inhibits  BoNT  Zinc  Metalloprotease  Activity:  A  Novel  and  Specific  Immunotherapeutic 
Approach to Botulism 
CDR3 of VHH has been shown to be penetrable into an active-site pocket of a target enzyme which 
would never be reached by a large, conventional antibody [106,107]. Consequently, the camelid VHH 
antibody  fragments  have  been  shown  to  be  potent  enzyme  inhibitors  [108,109].  Because  of  its 
characteristics [small size (~15–20 kDa), high tissue-penetrating ability, high yield from an expressed Toxins 2011, 3                         
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system such as E. coli (5–10 mg per mL), and high stability], the single domain antibody (sdAb) has 
drawn much attention regarding its use as a therapeutic antibody in human cancers, infectious diseases, 
and intoxications, particularly those caused by toxic enzyme molecules [97,110,111] or toxic small 
molecules such as puffer fish tetrodotoxin [112]. The camel VHH (Nanobody
®, Ablynx) specific to von 
Willebrand factor has been found to be safe in human subjects (no adverse reaction) in the phase I 
clinical trial [62]. The safety should be due to the high degree of sequence homology between human 
VH and camel VHH immunoglobulin frameworks (FRs) which is >80% [111]. The small size of the 
antibody is necessary not only for high tissue penetrating ability but also in having a more defined 
antigen binding site than the Fv of the conventional antibody or recombinant ScFv [113].  
Recently,  we  have  constructed  a  humanized-camel  VH/VHH  phage  display  library  [97]. 
Complementary DNA prepared from mRNA of a Camelus dromedrarius was used as a template for 
PCR amplification of the gene sequences coded for camel VH/VHH. However, primers used in the 
PCR  amplification  were  degenerate  primers  designed  from  all  families  of  human  VH  and  JH 
sequences including VH 1a, 1b, 1c, 1d, 2a, 2b, 3a, 3b, 3c, 4a, 4b, 5a, 6a and 7a and JH3, J6 and  
J1245  [90].  The  human  primers  created  an  amplification  constraint  during  the  polymerase  chain 
reaction which only the human-like camel VH/VHH (humanized) sequences were amplified [97]. VHH 
that bound specifically and neutralized the enzymatic activity to BoNT/A light chain was produced 
from a non-suppressor E. coli clone carrying recombinant VHH-phagemid that had been selected from 
the humanized-camel VH/VHH display library. The epitope of the VHH was found to be a peptide 
located  at  the  immediate  vicinity  of  the  BoNT/A  enzymatic  active  site.  Molecular  docking  and 
interface binding revealed that the VHH inserted its CDR3 into the toxic metalloprotease cleft [97]. The 
VHH has high sequence homology to the human VH sequences [97]. Therefore, the single domain anti-
BoNT/A antibody should have high potential as a safe, as well as effective and specific therapeutic 
remedy for human botulism caused by the type A BoNT. Recently, VHH specific to toxoid of BoNT/A 
was  also  produced  from  a  phage  display  library  constructed  from  B  cells  of  a  non-immune  
llama [114] as well as a llama immunized with the BoNT toxoid [115]. It is known, however, that there 
are sequence variations of the BoNT catalytic domain within the areas near to the enzymatic groove, 
and these variations have contributed to substrate specificity of different BoNT subtypes. Thus the 
humanized VHH that blocks the enzymatic activity of BoNT/A subtype should not cross-neutralize the 
other  BoNT  subtypes.  Nevertheless,  the  same  strategy  [97]  can  be  applied  for  production  of 
humanized-camel VHH that inhibit other BoNT subtypes.  
5. Cell Penetrating Antibody (Transbody) 
It is known that the enzymatic active site of the BoNT light chain is only exposed after the light 
chain has been released into the cytoplasm of the affected neuronal cells [14]. Therefore, the BoNT 
enzymatic cleft is inaccessible by the extracellular antibody. This problem can be overcome by making 
the VHH into a cell-penetrating format or ―Transbody‖. For this procedure, VHH is linked molecularly 
to a suitable cell-penetrating peptide (CPP) [116–118]. CPP is a short peptide that can be conjugated to 
various cargo molecules including proteins, antibody, nucleic acids, plasmid, and siRNA [119]. The 
CPP directs its cargo (in the form of a chimeric molecule) into the cytosol without causing cellular 
damage [118] by as yet unknown mechanism(s) [120–124]. CPPs have become a promising vehicle for Toxins 2011, 3                         
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cellular  uptake  of  therapeutic  molecules  [125].  In  addition,  CPP  sequences  can  be  modified  for 
delivering the cargoes to different subcellular compartments [126]. Various CPPs and their amino acid 
sequences have been listed elsewhere [127]. Recently, a cpp-plasmid platform has been established in 
our laboratory  [118].  The coding sequence of  the VHH that has  been shown to  inhibit the BoNT 
enzymatic activity can be molecularly linked to a CPP coding sequence using the plasmid platform. 
The CPP-VHH fusion protein is expected not only to traverse across the neuronal cell membrane into 
the cell but also to retain the BoNT inhibitory activity which would block the intracellular enzymatic 
target.  This  approach  has  high  potential  as  a  novel  and  specific  immunotherapeutic  strategy  for  
human botulism.  
6. Conclusions 
Treatment  of  human  botulism  is  supportive  and  symptomatic.  Passively  administered  
animal-derived anti-BoNT neutralizes circulating botulinum neutrotoxin by inhibiting binding of the 
toxin to neuronal receptors. The antibody cannot inhibit directly the proteolytic activity of the toxin 
that has gained cellular entry. In order to be mostly effective the anti-BoNT must be given at the 
earliest phase of the illness. The supply of the antitoxin is limited and not always available. Moreover, 
the animal protein induces adverse reactions in the recipient. A humanized single domain monoclonal 
transbody  (cell  penetrating  VHH)  that  binds  and  blocks  the  zinc  metalloprotease  activity  of  the 
intracellular BoNT specifically and directly, and does not cause the undesirable side effects, should be 
a novel and better immunotherapeutic remedy for human botulism.  
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